Trial
NCT04631601
Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Amgen
Collaborators
—
Condition
Metastatic Castration-resistant Prostate Cancer
Intervention
Acapatamab
Why stopped
Amgen made a business decision to discontinue all AMG 160 clinical trials. This decision is not related to safety.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-07